Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299234 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
A Phase 4 study, sponsored by Monarch Medical Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00299234 is a Phase 4 study that was terminated before completion, run by Monarch Medical Research. The registered enrollment target is 1 participants.
The verdict
NCT00299234, a Phase 4 study, was terminated before completion, sponsored by Monarch Medical Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine (1.8 mg/kg) for the management of chemotherapy-related acquired attentional disorders in children who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on ADHD symptoms in children with chemo-related acquired attentional disorders.
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299234
The ClinicalTrials.gov registry entry for NCT00299234 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Monarch Medical Research, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00299234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299234 about?
NCT00299234 is a clinical study titled "Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL". This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine (1.8 mg/kg) for the management of chemotherapy-related acquired attentional disorders in children who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on ADHD symptoms in childr...
What is the current status of trial NCT00299234?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00299234?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00299234?
This trial is sponsored by Monarch Medical Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.